Searched for: in-biosketch:true
person:wisnit01
In vivo imaging of amyloid plaques in AD and prion disease model mice [Meeting Abstract]
Wisniewski, T; Sigurdsson, EM; Wadghiri, YZ; Carp, R; Tang, CY; Turnbull, DH; Mathis, C; Klunk, WE; Gan, WB; Sadowski, M
ISI:000220589800105
ISSN: 0197-4580
CID: 42446
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease
Helpern, Joseph A; Lee, Sang-Pil; Falangola, Maria F; Dyakin, Victor V; Bogart, Adam; Ardekani, Babak; Duff, Karen; Branch, Craig; Wisniewski, Thomas; de Leon, Mony J; Wolf, Oliver; O'Shea, Jacqueline; Nixon, Ralph A
The cerebral deposition of amyloid beta-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1). transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of beta-amyloid in several brain regions, starting from 10 weeks of age; 2). transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of Abeta-peptide without beta-amyloid deposition; and 3). nontransgenic (NTg) littermates as controls. The transverse relaxation time T(2), an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T(1) values or proton density were detected between any groups of mice. These results indicate that T(2) may be a sensitive marker of abnormalities in this transgenic mouse model of AD
PMID: 15065253
ISSN: 0740-3194
CID: 42285
Prion protein ubiquitination in scrapie infection [Meeting Abstract]
Wong, BS; Kang, SC; Brown, DR; Whiteman, M; Li, R; Pan, T; Perry, G; Wisniewski, T; Sy, MS
ISI:000189078700166
ISSN: 0022-3042
CID: 42488
Detection of Alzheimer's amyloid lesions in transgenic mice by magnetic resonance imaging [Meeting Abstract]
Sigurdsson, EM; Wadghiri, YZ; Li, YS; Elliott, JI; Tang, CY; Aguilnaldo, G; Duff, K; Pappolla, M; Watanabe, M; Scholtzova, H; Turnbull, DH; Wisniewski, T
ISI:000188844200032
ISSN: 0197-4580
CID: 42486
A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations
Dowjat, Wieslaw K; Kuchna, Izabela; Wisniewski, Thomas; Wegiel, Jerzy
A novel presenilin-1 (PS1) mutation (P117S) in an American pedigree is described. We compare clinical, neuropathological and cell culture phenotypes produced by this mutation with another codon 117 mutation that was earlier discovered by our group in a Polish kindred. Both mutations are associated with an unusually severe Alzheimer disease (AD) phenotype, with the onset starting before the third decade of life, rapid disease progression and acute presentation of clinical symptoms. The severity of clinical phenotype was closely correlated with the abundance of pathology: massive deposition of Abeta42 in plaques, severe neurofibrillary degeneration and neuronal loss. When overexpressed in mouse neuroblastoma N2a cells, both mutations caused loss of an ability to promote neurite outgrowth and produced an increase in the ratio of secreted Abeta42/40 amyloid peptides. In stably transfected N2a cell lines only mutant proteins were endoproteolytically cleaved indicating some dependability of this process on the presence of mutation. Taken together, our results show that clinical and cell culture phenotypes produced by these 2 codon 117 mutations are closely related suggesting that the pathogenic action of PS1 may involve effect on neurite outgrowth and endoproteolytic cleavage of the full-length protein. Given the high potency in vivo and in vitro of both codon 117 mutations, this site of PS1 must be particularly important for its normal/pathogenic function
PMID: 15004326
ISSN: 1387-2877
CID: 45287
100 questions and answers about Alzheimer's disease
Sadowski M; Wisniewski T
Boston : Jones & Bartlett, 2004
Extent: 214 p.
ISBN: 0763732540
CID: 763
Prion diseases
Chapter by: Sadowski M; Verma A; Wisniewski T
in: Neurology in clinical practice by Bardley WG [Eds]
Philadelphia : Butterworth-Heinemann, 2004
pp. 1613-1650
ISBN: 0750674695
CID: 3167
In vivo magnetic resonance of amyloid plaques in Alzheimer's disease model mice
Chapter by: Sigurdsson, E; Wadghiri, YZ; Sadowski, M; Elliott, JI; Li, YS; Scholtzova, H; Tang, CY; Aguinaldo, G; Duff, K; Turnbull, DH; Wisniewski, T
in: The living brain and Alzheimer's disease by Hyman BT; Demonet J-F; Christen Y [Eds]
Berlin : Springer, 2004
pp. 47-59
ISBN: 3540211586
CID: 4970
Detection of prion amyloid deposits in vivo
Sadowski, Marcin; Pankiewicz, Joanna; Scholtzova, Henrieta; Tsai, Julia; Carp, Richard I.; Meeker, Cliff H.; Gan, Wen-Biao; Klunk, William E.; Mathis, Chester A.; Shao, Li; Debnath, Manik; Wisniewski, Thomas
BIOSIS:PREV200600010605
ISSN: 0028-3878
CID: 97609
Blocking the chaperoning effect of apolipoprotein E reduces beta-amyloid load in Alzheimer's disease transgenic mice
Sadowski, Marcin; Pankiewicz, Joanna; Scholtzova, Henrieta; Ripellino, James A.; Schmidt, Stephen D.; Mathews, Paul W.; Sigurdsson, Einar M.; Wisniewski, Thomas
BIOSIS:PREV200600010794
ISSN: 0028-3878
CID: 97610